Scinai Immunotherapeutics Reports Strong First-Half 2025 Results with Revenue Growth and Improved Cash Position

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported substantial financial improvements for the first half of 2025, with revenues reaching $773,000 compared to $284,000 in the prior-year period, reflecting continued growth in its contract development and manufacturing organization (CDMO) business. The company's research and development expenses decreased significantly to $1.24 million from $2.79 million, while marketing, general and administrative expenses increased to $1.26 million from $1.00 million.

The net loss narrowed to $4.13 million compared to $4.48 million a year earlier, demonstrating improved operational efficiency. The company's cash position strengthened considerably, with cash and equivalents totaling $989,000 as of June 30, 2025. Additionally, Scinai raised an additional $4.2 million in July and August under its Standby Equity Purchase Agreement, significantly enhancing liquidity for future operations and development programs.

Scinai advanced its anti-IL-17 NanoAb program during the reporting period, filing new patents under its collaboration with Max Planck. The company is actively pursuing up to €27 million in grant funding to support clinical trials and pipeline development, which could accelerate the commercialization of its innovative inflammation and immunology treatments. The CDMO unit demonstrated strong performance, booking $1.0 million in service orders through August 2025, indicating growing demand for its biological drug development and manufacturing services.

The financial results and strategic developments position Scinai for continued growth in both its therapeutic development and CDMO business units. The improved cash position provides the company with greater flexibility to advance its pipeline while maintaining operational stability. Investors and stakeholders can access additional information through the company's newsroom at https://ibn.fm/SCNI.